Long non-coding RNAs in cardiac hypertrophy and heart failure: functions, mechanisms and clinical prospects

Nat Rev Cardiol. 2024 May;21(5):326-345. doi: 10.1038/s41569-023-00952-5. Epub 2023 Nov 20.

Abstract

The surge in reports describing non-coding RNAs (ncRNAs) has focused attention on their possible biological roles and effects on development and disease. ncRNAs have been touted as previously uncharacterized regulators of gene expression and cellular processes, possibly working to fine-tune these functions. The sheer number of ncRNAs identified has outpaced the capacity to characterize each molecule thoroughly and to reliably establish its clinical relevance; it has, nonetheless, created excitement about their potential as molecular targets for novel therapeutic approaches to treat human disease. In this Review, we focus on one category of ncRNAs - long non-coding RNAs - and their expression, functions and molecular mechanisms in cardiac hypertrophy and heart failure. We further discuss the prospects for this specific class of ncRNAs as novel targets for the diagnosis and treatment of these conditions.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't
  • Research Support, N.I.H., Extramural

MeSH terms

  • Cardiomegaly / genetics
  • Heart Failure* / diagnosis
  • Heart Failure* / genetics
  • Heart Failure* / therapy
  • Humans
  • RNA, Long Noncoding* / genetics
  • RNA, Untranslated / genetics

Substances

  • RNA, Long Noncoding
  • RNA, Untranslated